DBV Technologies (NASDAQ:DBVT – Get Free Report) and Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.
Profitability
This table compares DBV Technologies and Jasper Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DBV Technologies | -815.73% | -106.07% | -76.17% |
| Jasper Therapeutics | N/A | -67.64% | -58.53% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for DBV Technologies and Jasper Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DBV Technologies | 0 | 0 | 2 | 0 | 3.00 |
| Jasper Therapeutics | 0 | 0 | 9 | 0 | 3.00 |
Valuation and Earnings
This table compares DBV Technologies and Jasper Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DBV Technologies | $15.73 million | 6.53 | -$72.73 million | ($4.50) | -1.11 |
| Jasper Therapeutics | N/A | N/A | -$64.46 million | ($4.86) | -1.07 |
Jasper Therapeutics has lower revenue, but higher earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are owned by institutional investors. 1.9% of DBV Technologies shares are owned by company insiders. Comparatively, 2.7% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
DBV Technologies has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.
Summary
Jasper Therapeutics beats DBV Technologies on 10 of the 12 factors compared between the two stocks.
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
About Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
